Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due ...

Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

As most of you know, our lead candidate OpRegen for patients with dry AMD with geographic atrophy is an allogeneic cell transplant comprised of RPE cells. OpRegen is delivered as a suspension to ...

The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... of photoreceptors and retinal pigment epithelial (RPE) cells in the central portion of the retina ...

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight ... and retinal pigment epithelial (RPE) cells, the central portion of ...

Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage Cell Therapeutics Inc Jack Allen; Analyst; Robert W. Baird & Co Inc Thank ...

Posterior cortical atrophy (PCA) is caused by damage that builds up in the brain cells at the back of the brain. This is the part of our brain that processes information from our eyes, and allows us ...